Sarepta (NAS: SRPT) popped as much as 7% on Wednesday to nearly $29 a share. That may seem like a nice boost, but Piper Jaffray has the company going up to somewhere between $60 and $80 in the near term and, staggeringly, suggests the potential for the stock to hit as high as $160 per share. In this video, Motley Fool health-care analyst David Williamson talks about how this relates to the company's tremendous results with its Duchenne muscular dystrophy drug eteplirsen, and how specific catalysts in the weeks and months to come could propel shares higher.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach in any sector is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article 1 Biotech Wall Street Thinks Has Multibagger Potential originally appeared on Fool.com.
Brenton Flynn owns shares of Sarepta Therapeutics. David Williamson has no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.